Dr. Reddy’s Lab launches Versavo in India

19 Aug 2019

Dr. Reddy's Laboratories has launched Versavo (bevacizumab), a biosimilar of Roche's Avastin in India, indicated for the treatment of several types of cancers (metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, metastatic breast cancer and epithelial ovarian, fallopian tube and primary peritoneal cancer). The company’s Versavo is available in strengths of 100mg and 400mg single use vials.

The company now has six biosimilar products commercialized in India and various emerging markets and an active development pipeline of several biosimilar products in the oncology and immunology space.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Related Dr. Reddys Laboratories Ltd. Links:

Dr. Reddys Lab Share Price

4574.30 73.50 (1.63%) Mar 04, 18:59
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 618.65
Dr. Reddys Lab 4574.30
Lupin 1048.15
Piramal Enterprises 1956.90
Cadila Healthcare 449.00
View more..
Sensex vs Dr. Reddys Lab
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback